News
Michael Bader is new "Foreign Legal Counsel" in China
05. February 2021
We are proud to be one of the very few European law firms to be registered with Michael Bader at the Chongqing Judicial Bureau as "Foreign Legal Counsel" of ZHH | Zhonghao Law Firm.
ZHH is one of the leading commercial law firms in China with offices in Beijing, Chongqing, Shanghai, Chengdu, Guiyang and Hong Kong and a member of LAWorld.
This cooperation ensures that our Swiss and European clients receive the same high standard of advice and expertise in China as in our home market and strengthens our China Desk in Switzerland.
New Team member in Bern und Zurich
04. December 2020
Bader Gnehm & Partner is pleased to welcome attorney at law Cheryl De-Souza to the Berne team and attorney at law Victoria Marty to the Zurich team as of December 1, 2020.
Further information on attorneys Cheryl De-Souza and Victoria Marty and our entire team can be found here.
BGP advises on the execution of an international sales and trade finance transaction
20. November 2020
BGPartner advises an international foreign oil and gas company on the execution of a transcontinental sale of an oil drilling rig. The complex deal was executed under Swiss law und involved industry and trade finance parties across several jurisdictions.
The seller and exporter was advised in all Swiss legal matters regarding the execution by BGPartner. The team was led by Michael Bader (Senior Partner) and furthermore involved were Oliver Gnehm (Partner) and Olivier Bula (Partner).
BGPartner’s Trade & Export Finance team features experienced specialists delivering comprehensive legal and negotiation services to market players and industries involved in international commerce, trade and export finance.
More information can be found here.
BGP advises Memo Therapeutics regarding its CHF 14 Mio. Series B financing round
11. November 2020
Bader Gnehm & Partner advised Memo Therapeutics Ltd in a CHF 14 million Series B financing round, involving the investors Swisscanto Invest, BERNINA BioInvest, Redalpine, Jaquet Partners and Schroder Adveq.
Memo Therapeutics Ltd, an innovator in the field of antibody discovery and immune repertoire analysis, intends to use the proceeds to further develop its lead antibody candidate "MTX-COVAB" for the treatment of COVID-19.
Memo Therapeutics Ltd was advised in all legal matters with regard to the Series B financing round by Bader Gnehm & Partner. The team consisted of Oliver Gnehm (Partner), Denis A. Parvex (Associate) and Thomas Gysin (Associate).
Bader Gnehm & Partner has been repeatedly awarded as top law firm in the area of "Private Equity and Venture Capital".
The press release of Memo Therapeutics Ltd can be found here.
Araris Biotech raises CHF 15.2 mio in Seed financing round
06. November 2020
Araris Biotech Ltd has obtained CHF 15.2 million in a Seed financing round from the investors Pureos Bioventures, 4BIO Capital, btov Partners, Redalpine, VI Partners and Schroder Adveq.
Araris Biotech Ltd, a company pioneering antibody-drug conjugate (ADC)-linker technology, intends to use the proceeds to support advancement of lead ADCs into preclinical and clinical development.
Araris Biotech Ltd was advised in all legal matters with regard to the Seed financing round by Bader Gnehm & Partner. The team consisted of Oliver Gnehm (Partner), Denis A. Parvex (Associate) and Thomas Gysin (Associate).
Bader Gnehm & Partner has been repeatedly awarded as top law firm in the area of "Private Equity and Venture Capital".
The press release of Araris Biotech Ltd can be found here: Araris Biotech